O-1656
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C22H36O2 |
| Molar mass | 332.528 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
O-1656 is a cannabinoid agonist which was invented by Billy R Martin and Raj K Razdan at Organix Inc in 2002. It is moderately selective for the CB2 receptor with a CB1 receptor affinity of 18 nM and a CB2 receptor affinity of 2 nM.[1][2][3] Since it has a cycloheptyl ring attached to the phenol core, it falls outside the definition of a "cyclohexylphenol derivative", but may still be controlled by generic legislation in some jurisdictions.
See also
References
- ^ WO application 03091189, Martin BR, Razdan RK, "Cannabinoids", published 6 November 2003, assigned to University of Virginia
- ^ Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, Razdan RK, Martin BR (May 2002). "Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 679–89. doi:10.1124/jpet.301.2.679. PMID 11961073. S2CID 12741224.
- ^ Adam J, Cowley PM, Kiyoi T, Morrison AJ, Mort CJ (2006). "Recent progress in cannabinoid research". Progress in Medicinal Chemistry. 44: 207–329. doi:10.1016/S0079-6468(05)44406-9. ISBN 9780444517371. PMID 16697899.